-
1
-
-
84889873119
-
A randomized trial of genotype-guided dosing of warfarin
-
Pirmohamed M, Burnside G, Eriksson N et al. A randomized trial of genotype-guided dosing of warfarin. N. Engl. J. Med. 369(24), 2294-2303 (2013).
-
(2013)
N. Engl. J. Med.
, vol.369
, Issue.24
, pp. 2294-2303
-
-
Pirmohamed, M.1
Burnside, G.2
Eriksson, N.3
-
2
-
-
84889824971
-
A pharmacogenetic versus a clinical algorithm for warfarin dosing
-
Kimmel SE, French B, Kasner SE et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N. Engl. J. Med. 369(24), 2283-2293 (2013).
-
(2013)
N. Engl. J. Med.
, vol.369
, Issue.24
, pp. 2283-2293
-
-
Kimmel, S.E.1
French, B.2
Kasner, S.E.3
-
3
-
-
84856699090
-
Executive summary: Antithrombotic Therapy and Prevention of Thrombosis (9th Edition): American college of chest physicians evidence-based clinical practice guidelines
-
Guyatt GH, Akl EA, Crowther M et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis (9th Edition): American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(Suppl. 2), S7-S47 (2012).
-
(2012)
Chest
, vol.141
, Issue.SUPPL. 2
-
-
Guyatt, G.H.1
Akl, E.A.2
Crowther, M.3
-
4
-
-
0037732826
-
-
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy
-
Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J. Am. Coll. Cardiol. 41(9), 1633-1652 (2003).
-
(2003)
J. Am. Coll. Cardiol.
, vol.41
, Issue.9
, pp. 1633-1652
-
-
Hirsh, J.1
Fuster, V.2
Ansell, J.3
Halperin, J.L.4
-
5
-
-
0028210729
-
Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9
-
Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4(1), 39-42 (1994).
-
(1994)
Pharmacogenetics
, vol.4
, Issue.1
, pp. 39-42
-
-
Rettie, A.E.1
Wienkers, L.C.2
Gonzalez, F.J.3
Trager, W.F.4
Korzekwa, K.R.5
-
6
-
-
0033608466
-
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
-
Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353(9154), 717-719 (1999).
-
(1999)
Lancet
, vol.353
, Issue.9154
, pp. 717-719
-
-
Aithal, G.P.1
Day, C.P.2
Kesteven, P.J.3
Daly, A.K.4
-
7
-
-
21144448879
-
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
-
Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22), 2285-2293 (2005).
-
(2005)
N. Engl. J. Med.
, vol.352
, Issue.22
, pp. 2285-2293
-
-
Rieder, M.J.1
Reiner, A.P.2
Gage, B.F.3
-
8
-
-
47949086046
-
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
-
Gage BF, Eby C, Johnson JA et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326-331 (2008).
-
(2008)
Clin. Pharmacol. Ther.
, vol.84
, Issue.3
, pp. 326-331
-
-
Gage, B.F.1
Eby, C.2
Johnson, J.A.3
-
9
-
-
60849097257
-
Estimation of the warfarin dose with clinical and pharmacogenetic data
-
International Warfarin Pharmacogenetics Consortium
-
International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009).
-
(2009)
N. Engl. J. Med.
, vol.360
, Issue.8
, pp. 753-764
-
-
Klein, T.E.1
Altman, R.B.2
-
10
-
-
63449117825
-
A genome-wide association study confirms VKORC1 CYP2C9 and CYP4F2 as principal genetic determinants of warfarin dose
-
Takeuchi F, Mcginnis R, Bourgeois S et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5(3), e1000433 (2009).
-
(2009)
PLoS Genet.
, vol.5
, Issue.3
-
-
Takeuchi, F.1
McGinnis, R.2
Bourgeois, S.3
-
11
-
-
59649117935
-
The largest prospective warfarin-treated cohort supports genetic forecasting
-
Wadelius M, Chen LY, Lindh JD et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4), 784-792 (2009).
-
(2009)
Blood
, vol.113
, Issue.4
, pp. 784-792
-
-
Wadelius, M.1
Chen, L.Y.2
Lindh, J.D.3
-
12
-
-
77953304931
-
Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study)
-
Epstein RS, Moyer TP, Aubert RE et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J. Am. Coll. Cardiol. 55(25), 2804-2812 (2010).
-
(2010)
J. Am. Coll. Cardiol.
, vol.55
, Issue.25
, pp. 2804-2812
-
-
Epstein, R.S.1
Moyer, T.P.2
Aubert, R.E.3
-
13
-
-
80052930568
-
Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy
-
Gong IY, Tirona RG, Schwarz UI et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 118(11), 3163-3171 (2011).
-
(2011)
Blood
, vol.118
, Issue.11
, pp. 3163-3171
-
-
Gong, I.Y.1
Tirona, R.G.2
Schwarz, U.I.3
-
14
-
-
36549030324
-
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation
-
Anderson JL, Horne BD, Stevens SM et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22), 2563-2570 (2007).
-
(2007)
Circulation
, vol.116
, Issue.22
, pp. 2563-2570
-
-
Anderson, J.L.1
Horne, B.D.2
Stevens, S.M.3
-
15
-
-
79959189730
-
A randomized controlled trial of genotype-based Coumadin initiation
-
Burmester JK, Berg RL, Yale SH et al. A randomized controlled trial of genotype-based Coumadin initiation. Genet. Med. 13(6), 509-518 (2011).
-
(2011)
Genet. Med.
, vol.13
, Issue.6
, pp. 509-518
-
-
Burmester, J.K.1
Berg, R.L.2
Yale, S.H.3
-
16
-
-
84862777241
-
A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II)
-
Anderson JL, Horne BD, Stevens SM et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 125(16), 1997-2005 (2012).
-
(2012)
Circulation
, vol.125
, Issue.16
, pp. 1997-2005
-
-
Anderson, J.L.1
Horne, B.D.2
Stevens, S.M.3
-
17
-
-
84901250896
-
Ethnicity-specific pharmacogenetics: The case of warfarin in African Americans
-
doi:10.1038/tpj.2013.34 Epub ahead of print
-
Hernandez W, Gamazon ER, Aquino-Michaels K et al. Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. Pharmacogenom. J. doi:10.1038/tpj.2013.34 (2013) (Epub ahead of print).
-
(2013)
Pharmacogenom. J.
-
-
Hernandez, W.1
Gamazon, E.R.2
Aquino-Michaels, K.3
-
18
-
-
84866738499
-
Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): Rationale and study design
-
Do EJ, Lenzini P, Eby CS et al. Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J. 12(5), 417-424 (2012).
-
(2012)
Pharmacogenomics J.
, vol.12
, Issue.5
, pp. 417-424
-
-
Do, E.J.1
Lenzini, P.2
Eby, C.S.3
-
19
-
-
79959260078
-
Clinical trials for pharmacogenomics testing for warfarin dosing: Relevance to general community practices
-
Sidiropoulos N, Wu AH. Clinical trials for pharmacogenomics testing for warfarin dosing: relevance to general community practices. Genet. Med. 13(6), 505-508 (2011).
-
(2011)
Genet. Med.
, vol.13
, Issue.6
, pp. 505-508
-
-
Sidiropoulos, N.1
Wu, A.H.2
|